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Abstract
Background:  The use of natural health products, such as vitamins, minerals, and herbs, by
Canadians has been increasing with time. As a result of consumer concern about the quality of
these products, the Canadian Department of Health created the Natural Health Products (NHP)
Regulations. The new Canadian regulations raise questions about whether and how the NHP
industry will be able to comply and what impact they will have on market structure. The objectives
of this study were to explore who in the interview sample is complying with Canada's new NHP
Regulations (i.e., submitted product licensing applications on time); and explore the factors that
affect regulatory compliance.
Methods: Twenty key informant interviews were conducted with employees of the NHP industry.
The structured interviews focused on the level of satisfaction with the Regulations and perceptions
of compliance and non-compliance. Interviews were tape recorded and then transcribed verbatim.
Data were independently coded, using qualitative content analysis. Team meetings were held after
every three to four interviews to discuss emerging themes.
Results: The major finding of this study is that most (17 out of 20) companies interviewed were
beginning to comply with the new regulatory regime. The factors that contribute to likelihood of
regulatory compliance were: perceptions and knowledge of the regulations and business size.
Conclusion: The Canadian case can be instructive for other countries seeking to implement
regulatory standards for natural health products. An unintended consequence of the Canadian
NHP regulations may be the exit of smaller firms, leading to industry consolidation.
Background
Consumer use of vitamins, minerals, and herbs increased
dramatically during the 1990s. A 2001 survey found that
75% of Canadians had used a natural health product
(NHP), such as vitamins, minerals, and/or herbal reme-
dies, for a health condition[1]. In the United States, the
use of herbals increased 380% during the period of 1990
to 1997[2]. As the use of these products increased, so did
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concern among consumers over the quality and efficacy of
NHPs.
The Canadian federal department of health, Health Can-
ada, conducted extensive consultations with industry
members, consumers, health care providers, and research-
ers to assist in developing regulations specifically for
NHPs. Health Canada began implementing the NHP reg-
ulations on January 1, 2004[3]. The new NHP regulations
classify NHPs as a sub-category of drugs, and apply to
products commonly known as traditional herbal reme-
dies, traditional Chinese, Ayurvedic, and Native North
American medicines, homeopathic medicines, and vita-
min and mineral supplements. Health Canada seeks "to
ensure that all Canadians have ready access to natural
health products that are safe, effective, and of high quality,
while respecting freedom of choice and philosophical and
cultural diversity"[4]. The regulations specify industry
requirements for selling NHPs in Canada, including man-
ufacturing, packaging, labelling, storing, importing, and
distributing specifications.
Prior to January 2004, NHPs were officially regulated pur-
suant to the Food and Drugs Act (1985), mainly depending
on whether medicinal claims were made. However, many
companies did not follow either the food or drug regula-
tions and neither were rigorously enforced. The NHP reg-
ulations are viewed as being more strict than the food
product regulations because companies must provide evi-
dence of safety, efficacy, and quality to Health Canada,
but less strict than the regulation of drugs in the country.
The regulations represent government monitoring over
the sale of NHPs via pre-market approval mechanisms.
Current debate is focused on what impact these regula-
tions will have on the industry and how once their impact
is known, this will shape the regulations. Very little is
known about how the industry will respond to the NHP
Regulations. This paper hopes to fill in some of the gaps
by examining how industry is responding the the regula-
tions.
II. Background
A number of factors that affect compliance with new reg-
ulations have been identified in the literature including:
perceptions of the law (whether the law is thought to be
necessary, whether those having to comply with the regu-
lations agree with the law and feel they would benefit
from the law), the perceptions of the regulated companies
towards compliance with the law (whether noncompli-
ance will result in penalties, whether the type and amount
of compliance is clearly stated in the law, and whether
compliance can be supported), as well as whether the law
specifies enforcement activity and the regulated respond
to the law[5]. Compliance of those being regulated has
been identified as an important stage of policy implemen-
tation and achieving the goals of a regulation[6]. Thus,
this study investigates whether defined factors for individ-
ual compliance behavior are applicable to industry com-
pliance with the new NHP Regulations. Before detailing
the findings of the study, additional information about
the NHP Regulations and the NHP industry is provided
for context.
A. The Natural Health Products (NHP) regulations
On of January 1, 2004, the NHP regulations became law
administered by the Natural Health Products Directorate
(NHPD) of Health Canada. Any company that sells a fin-
ished form of a NHP on the Canadian market must sub-
mit a product licence application (PLA) to the NHPD. The
PLA must contain evidence for the safety, efficacy, and
quality of the product. For example, specific baseline stud-
ies are required (unless the product already has a signifi-
cant history of safe use in humans) such as repeat dose
toxicity studies, genotoxicity studies and reproductive tox-
icity studies which are performed according to interna-
tional standards such as the World Health Organization,
International Conference on Harmonization and/or the
Organization for Economic Cooperation and Develop-
ment[4]. The application must also include information
supporting the health claim of the NHP. An eight-digit
natural product number (NPN) or a Drug Identification
Number-Homeopathic Medicine (DIN-HM) (for homeo-
pathic medicines) is issued by the NHPD to the company
upon review and acceptance of the provided evidence.
According to the NHP Regulations (2003), the NPN or
DIN-HM must be displayed on the product label when
sold on the Canadian market as indication of market
authorization. All Canadian products which were on the
market on January 1, 2004 (when the new regulations
became law) have up to six years to obtain product
licences. However, products new to the market after that
date require pre-approval prior to sale. The Canadian
NHP market is estimated to include up to 50,000 individ-
ual products, all of which must submit product licensing
applications (PLAs) to NHPD. This has created a substan-
tial backlog and as of January 2005 there were thousands
of application in cue waiting for NHPD assessment.
During the period of 2004 to 2010, Health Canada
decided to focus its activities by assigning all NHPs to six
"priority" categories based loosely on perceived risks asso-
ciated with the products in each category. Each priority
category has its own deadline for submitting PLAs in an
attempt to ensure that they arrive at NHPD throughout
the six year transition period. For example, Priority One
products are products meeting the definition of a natural
health product listed on the Therapeutic Products Directo-
rate's (TPD's) Listing of Drugs Currently Regulated as New
Drugs[7] and must comply with the NHP regulations byBMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
Page 3 of 11
(page number not for citation purposes)
June 30, 2004. Examples include glucosamine, and some
forms of devil's claw, dong quai, and ginseng[8]. That is,
companies that sell a product on this list must have
applied for a NPN by June 30, 2004. After this date, the
company will be subject to enforcement actions by the
Health Products and Food Branch Inspectorate (HPFBI),
such as voluntary disposal, voluntary detention, recall,
warning, stop sale or prosecution[9]. Any company that
wishes to bring a new product to market whose ingredi-
ents fall within the priority one category must receive pre-
approval prior to selling the new product in Canada.
The substances in this category are high priority because
Health Canada claims that little information exists on the
safety and efficacy of the use of these products for medic-
inal purposes. Companies that sell chondroitin and glu-
cosamine (Priority One products) in Canada were
specifically targeted to participate in this study. Chondroi-
tin and glucosamine products were chosen because: all
forms for all indications are clearly listed as Priority One
products (i.e., must meet the June 30th deadline); there are
many different brands currently available on the Cana-
dian market; and a significant amount of scientific evi-
dence supporting the efficacy of both chondroitin and
glucosamine in the management of osteoarthritis is avail-
able. Thus, industry members may be eager to register
these products in order to make health claims on their
packaging and promotion.
B. Overview of the NHP industry in Canada
Information on the NHP industry in Canada is limited
because NHPs are not part of the established health care
system in the country; neither the industry nor the govern-
ment monitor NHP sales as a distinct category, and pro-
vincial drug plans do not cover purchases of NHPs[1].
According to a business impact test (BIT) (2003) con-
ducted prior to the implementation of the Regulations for
Health Canada, the NHP industry is composed of mainly
small and cottage businesses. Fifty-five percent of
respondents in the BIT identified themselves as part of a
company with fewer than 19 employees and 75% of
respondents said their company had fewer than 50
employees. These percentages from the survey are said to
be indicative of the NHP industry in Canada.
The purpose of this paper is twofold: first, to explore who
in the study sample is complying with the Canadian NHP
Regulations (i.e., submitted product licensing applica-
tions on time); and second, to investigate factors that
affect regulatory compliance.
Methods
The study is an applied ethnography[10] that incorporates
qualitative research methods in order to better understand
the perceptions of NHP industry members in Canada.
This study explores the factors of firm compliance in sev-
eral novel ways. First, the study utilizes an ethnographic
approach that uses qualitative methods. Qualitative
methods, such as interviews, are particularly useful in
understanding complex social processes, such as the
implementation of federal regulations. Interviews are use-
ful for understanding human perception and behavior,
which is difficult to obtain from survey data. Second, the
study was conducted during the very early stage of imple-
mentation, rather than after full implementation. Third,
the study does not assume that the factors that affect com-
pliance will be the same for different business sizes and
activities.
Interview sample
Criterion-based, purposeful sampling[11] was used to
select NHP companies that are required to submit appli-
cations for NPNs. To be included in the study, a company
had to meet the following criteria: a) it sells finished
forms of chondroitin and/or glucosamine on the Cana-
dian market; b) it is required, according to the NHP Reg-
ulations, to submit PLAs for glucosamine and/or
chondroitin by the June 30, 2004, deadline; c) it has an
office located in Canada; and d) representatives are able to
participate in an interview conducted in English. There
were no exclusion criteria. Of the approximately 364 NHP
businesses in Canada, 67 met the eligibility criteria of the
study. From the 67 companies, companies were selective
chosen to ensure a maximum variation sample[11] with
respect to business activity/specialty, size, and location.
Data gathering
Semi-structured interviews were conducted either by tele-
phone or in-person. The person responsible for regulatory
affairs and/or writing the NPN applications was inter-
viewed in each case. The interviews were scheduled for
approximately one hour and were audio taped and tran-
scribed verbatim. Prior to the interview, each respondent
was mailed a survey to collect basic information about the
size of the company, number of NHPs they sell and details
about the glucosamine/chondroitin products they sell. At
the end of each interview, the interviewer reviewed the
survey with the respondent in an attempt to ensure that all
questions were answered accurately and fully. These ques-
tions remained fixed through out the study. See Addi-
tional file 1 for interview guide and survey questions.
The interviews focused on the perceptions of individuals
regarding the regulations, such as: whether the regulations
are necessary and whether they agree with the goal of the
regulations. The respondents were also asked about the
likelihood of regulatory enforcement and industry com-
pliance. The interview questions were developed based on
information from the BIT study, consensus among the
research team, and responses from participants early on inBMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
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the study. The specific interview questions changed as the
research proceeded in order to follow-up on information
and themes identified by participants as important. Inter-
views continued until a point of saturation was reached.
Saturation is the point in qualitative research where no
new information about key themes is emerging from new
interviews [11].
Company representatives interviewed
The president/owner, regulatory affairs manager, and/or
quality assurance personnel were interviewed at 20 of the
67 eligible companies. Thirteen companies were consid-
ered "unreachable" after leaving three voice messages for
the contact person at the company and 18 declined to par-
ticipate. The remaining 13 companies were not contacted
because saturation[11] had been reached after conducting
20 interviews (Figure 1).
NHP companies of various locations, specialties, and sizes
were included (Table 1). The majority of companies that
were involved in the study are based in Ontario (11 com-
panies), British Columbia (3 companies), and Quebec (3
companies). The remaining companies are located in
Alberta, Manitoba, or had head offices in the United
States. The different NHP specialties include manufactur-
ing (18 companies), distributing (11 companies), private
labelling (5 companies), formulating (4 companies), as
well as many others. These companies sell their products
in health food stores, large distribution chains, the inter-
net, and through health practitioners. Lastly, small,
medium, and large sized companies were involved in the
study.
Based on the BIT definition of business size, 9 companies
in the study are large, 6 are medium, and 5 are small busi-
nesses (Table 1). The majority of companies in the study
had annual sales of less than 10 million dollars, sold sev-
eral hundred NHP products and less than 100 DIN prod-
ucts on the Canadian market, began operations post
1991, and primarily focused product sales in Canada. The
study also captures companies in the extreme positions of
the NHP industry. For example, companies that have as
little as three to as high as 500 employees were involved
in the study as well as sales ranging from half a million to
over 200 million dollars. Given this, a range of percep-
tions can be described with confidence.
Companies Interviewed for the Study Figure 1
Companies Interviewed for the Study.
65 Companies Meet 
Eligibility Criteria
20 Companies
Interviewed
14 Companies
“Unreachable”
18 Companies
Refused
13 Companies
not Contacted 
27 People 
Interviewed
26 NHP 
Brands
8 Too busy 
4 No Reason Given 
2 Change in Company
2 Don’t do Research 
1 Don’t Know Enough 
1 Health Issues
~ 365 NHP Companies in 
CanadaBMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
Page 5 of 11
(page number not for citation purposes)
Data analysis
Data collected from the interviews were independently
analyzed, using qualitative content analysis[12], by three
different researchers (HL, HB, and NK). Content analysis
involves analyzing the interview transcripts by categoriz-
ing segments of the transcripts into topic areas[13,14]
Transcript segments can vary in size from a single word to
paragraphs. In the analysis, the were transcripts into sim-
ple sentences with subjects and predicates, called
"themes"[13]. Each theme was then placed in a topic cat-
egory based on its content. These themes cannot be iden-
tified  a priori, but rather must emerge from the data
collected. Large categories were further divided into sub-
categories creating a tree-diagram. Research team meet-
ings were held after every three interviews to discuss the
coding process and key themes emerging from the data.
The qualitative analysis software NVIVO[15] was used to
store and manage the data collected from interviews.
The perceptions of individuals from small and medium
companies have been combined and are referred to as
small and medium sized enterprises (SMEs), given the
similarity of the issues identified from their interviews.
The opinions of representatives of SMEs are compared
and contrasted to those of large firm representatives.
These opinions are portrayed via direct quotations from
interview participants.
Results
A. Business size and compliance with the Priority One 
products deadline
In this study, compliance is measured by whether a com-
pany submitted a product licence application to the
NHPD for chondroitin and/or glucosamine by the June
30, 2004, deadline. For the study sample, compliance
with the deadline varied according to business size (Table
2). For example, 3 SMEs were noncompliant with the
deadline (failed to submit a PLA by the deadline date), 4
SMEs were under complying (submitted a PLA after the
deadline date), 1 SME was semi-complying (some of com-
pany PLAs submitted by the deadline), and 3 SMEs were
compliant. In comparison, no large companies were non-
compliant or under complying, 5 were semi-complying,
and 4 were compliant. Important to note is that only
SMEs fall into the noncompliant and under compliant
category. Since compliance with the first NHPD deadline
varies with business size, the factors that affect compli-
ance are considered with respect to business size.
B. Perceptions of the NHP regulations
Whether the regulations are necessary
All employees interviewed agree with the goal of the
NHPD, that is, to ensure the safety, quality, and efficacy of
NHPs. The majority of participants felt that the regula-
tions are necessary for reasons such as establishing indus-
try standards and increasing consumer confidence in
NHPs. Many participants also stated that the regulations
Table 1: Key characteristics of the 20 interviewed companies.
Description # of Companies
Size
Small (< 19 employees) 5
Medium (20 to 49 employees) 6
Large (> 50 employees) 9
Annual Sales (Can $)
< 10 M 8
5 to 50.9 M 5
> 50 M 4
Confidential 3
# of Products
< 99 2
100–499 13
500–999 4
>1000 1
Market Focus
Local 0
Regional 1
National 15
International 9BMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
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would ensure a fair, level playing field. That is, any firm
that produces a NHP must abide by the NHP regulations,
and no longer has the option of complying with either the
food or drug standards.
Level of agreement with the NHP regulations
In general, participants agree with the intent of regula-
tions although the intensity of agreement varied with
business size.
Large firms
Overall, employees of large firms perceive the regulations
more positively than employees of SMEs. The majority of
participants from large firms stated they were satisfied
with the final version of the regulations in comparison to
participants from SMEs. An individual stated that the reg-
ulations were well written and that the NHPD had con-
sulted with other Directorates in Health Canada in order
to develop practical regulations.
On the other hand, some representatives from large com-
panies are disappointed with the time frames provided by
the NHPD but for different reasons than representatives
from SMEs. Large firm employees are frustrated that the
implementation stage is moving slowly:
the faster the weaker players get out of the business, the
better, from a commercial side or predatory side ... there's
only going to be 3 or 4 big players that are going to sur-
vive. We intend on being one of them. So I'm saying if
you're going to cause that, then do it faster. Quit slow
bleeding us. (6, Large)
Many feel that the regulations will increase the public's
confidence in the NHP products and thus benefit the NHP
industry in the long run, but the process of getting to that
position is painful:
I think it's guaranteeing the safety of the Canadian public,
and standardizing the industry...So in the long run, it's
going to be better for us. It's just going to be painful get-
ting there (6, Large).
SMEs
Several SME participants did not agree with the way the
regulations were being implemented. For example, many
participants stated that the regulations are too strict for the
level of risk NHPs pose to the general public. A represent-
ative from a SME said "I think that Health Canada is being
too safe with the products that have a long history of use
on safety...products that have been sold for so long with
very few adverse events being reported" (13, Medium).
Others expressed similar concerns:
No, I'm not [satisfied]. The major reason is I think it [the
NHP Regulations] is much too onerous for ... the level of
risk we pose to the general public... the vast majority of
whatever is being produced in the natural product indus-
try does not come anywhere close to drugs as far as the
safety issues are concerned (5, Small).
SMEs representatives are the most dissatisfied with the
NHP Regulations because they feel the regulations impose
the same level of control as the drug regulations in Can-
ada. They feel that individuals who wrote the regulations
had experience in the pharmaceutical industry and very
little experience in the NHP industry. The regulations are
described as impractical for small NHP businesses. One
participant stated, " [the NHP regulations] just lack rea-
sonable expectations for business. It [the NHPD]
approached the business as if we're all large drug manu-
facturers with millions of dollars of research and patents"
(7, Small). Similarly, many participants do not like that
the government considers NHPs a sub-set of drugs
because NHPs do not have the volume of sale, price mark-
up, and level of risk associated with pharmaceutical drugs.
As a result, many participants felt that small businesses
with few products would not be able to survive in the new
Table 2: Company Compliance Status for the Priority One compliance deadline of June 30, 2004.
Description Number of Businesses in each Category
Noncompliant (did not submit a PLA by June 30, 2004) 3 SMEs
Under Complying (sent in applications after June 30, 2004) 4 SMEs
Semi Compliant (ie. Company has more than one product, some 
PLAs submitted before June 30, other PLAs submitted after the date)
1 SMEs
5 Large
Compliant (submitted PLA by June 30, 2004) 3 SMEs
4 Large
TOTAL 20BMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
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regulatory environment. For example, a key informant
stated:
I've got roughly a hundred products...how many am I
going to lose? I would say I'm going to lose probably one
to two out of five products...will not meet the require-
ments of the Regulations...the fact there are no human
clinical trials done on those ingredients (7, Small)
Several key informants from SMEs stated that smaller
businesses in the industry produce niche products and
large firm produce standard vitamins and minerals. Since
smaller companies may not be able to afford to market
entire product lines, their innovative products may be lost
from the industry.
Another concern was the compliance timelines set out by
the NHPD. Small companies felt the timelines were too
short, especially those associated with the priority phase-
in strategy. There was also frustration expressed about
what was perceived as the changeable nature of what was
required and when:
I'm also concerned that their timelines are so tight. You
know, initially the priority one applications were sup-
posed to be in by June 1st, they extended it to June 30th,
and in June they put out that document saying, you know,
"if you submit an application before June 30th, then you
can sell the product. If you submit it after, you can't sell it
until you get your approval. (8, Medium)
C. Perceptions of compliance
Large firms
Only employees of large companies are concerned that
other firms in the NHP industry will fail to comply with
the new regulations. One participant stated that 99% of
his contacts are not changing their operating procedures
because they believe that the regulations are not going to
last. Another participant voiced a similar concern stating
that the backlog in product review is, in essence, prevent-
ing companies from launching novel products on the
Canadian market. As a result, some may disregard them in
order to survive as a company. Another said, "the tricky
part right now is to get everybody to buy into them [the
NHP regulations] and say, 'yes, we are operating in the
industry, these are the regulations we are going to abide by
and we all support it.' Like I said, the biggest danger to
these new regulations is mass non-compliance." (4a,
Large)
Enforcement and noncompliance
Large firms
Many participants feel that very few regulatory enforce-
ment actions are currently taking place. One person
stated, "they're [government officials] not doing any-
thing." (4b, Large) Many suggested little enforcement
action is occurring because of the large number of PLAs
the NHPD is currently processing and limited resources of
the government: "the HPFBI, the Inspectorate, has already
indicated they don't have the resources to be policing this,
so the reality is they are going to rely on people snitching,
and the industry has not typically snitched on each other."
(9, large) One individual felt that the enforcement actions
would take place once the backlog disappears, in approx-
imately five years.
Several participants were concerned about how the regu-
lations will be enforced in the future. Many are concerned
that compliance actions will be too strict, will focus on
only part of the NHP industry, and will be reactive rather
than proactive:
I think that they are going to enforce ... I can see probably
the companies that are spending the most and doing the
most are the ones that are going to be targeted. Because
they're also the higher profile ones. And that's how they
implement and how they enforce. (6, Large)
SMEs
Representative from SMEs were more certain that the reg-
ulations would be strictly enforced. A representative of a
small company stated that he was disappointed that peo-
ple are talking about enforcement issues. Instead, he
would like to see more discussion around how the govern-
ment can provide assistance to companies during the tran-
sition period:
The bottom line is, are we really to that point where we
have to talk about enforcement of companies that have
been in business for the better part of ten or twelve years?
... [the federal government should say] "There's going to
be a transition period and here's how we're going to help
you meet that. We're going to help you by coming out and
going through your place and telling what you need to
do...We'll come in to help you."(7, Small)
D. Other factors that affect compliance
Knowledge of the regulations
Large firms
Representatives from large firms were very knowledgeable
about details of the regulations, including how the regula-
tions were formed and the details and requirements in the
regulations. Many participants stated that the company
has either vitamin or mineral products with a Drug Iden-
tification Number (DIN) and thus are compliant with the
drug regulations under the Food and Drugs Act, of which
the NHP regulations are perceived to be a less strict ver-
sion. A participant stated, "a lot of it [the NHP regula-
tions] is common sense. It's having the people together,
that information that you already have within your com-BMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
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pany, putting it into a standard format, and submitting it
[to the NHPD]" (4a, Large). This individual continued by
explaining:
They [the NHPD] loosened up on their manufacturing
standards...where they tightened up was pre-product
approval. So the activities and the amount of information
needed to get pre-market approval of NHPs have
increased extremely. But I think that is in compensation
because the manufacturing standards were lowered. (4a,
Large)
SMEs
This group of companies revealed the most misinforma-
tion about the regulations compared to the other compa-
nies. For example, one participant thought Health Canada
inspectors would be testing all NHPs on the Canadian
market to ensure safety. Yet others were unaware of when
and how the regulations would be implemented.
Discussion
The major finding of this study is that 17 of 20 companies
are in the process of submitting PLAs to the NHPD. The
three noncompliant companies were SMEs, of which
none knew that they had failed to comply with the dead-
line.
Determining whether perceptions of the regulations,
including whether the law is necessary and the intensity of
agreement with the regulations, is an important factor for
compliance is difficult in this study because all partici-
pants felt the Regulations are necessary and agree with the
mandate of the NHPD. Despite general agreement with
the mandate, employees of SMEs were concerned about
how rigorously the regulations would be applied and the
potential negative impact on their businesses. In compar-
ison, large firm employees were satisfied with the stand-
ards and looked forward to full implementation. Despite
some misgivings expressed by some SMEs, the majority of
the companies in the sample were submitting PLAs, which
seemed to be at least in part because of their generally pos-
itive views of the regulations. Thus, perceptions of regula-
tions are an important compliance factor.
This study also addressed perceptions of noncompliance
and enforcement. Only representatives from SMEs were
certain that noncompliance with the regulations would
result in enforcement actions and indicated that this con-
tributed to their compliance. In contrast, large firm repre-
sentatives were confident that the regulations would not
be enforced and were concerned that other firms would
not comply with the regulations. Despite these beliefs,
large firms were complying with the regulations. This
means that neither the perception that noncompliance
will result in penalties, nor the likelihood of other firms
complying, affects the compliance of large firms.
The only factor that influences compliance for both large
firms and SMEs is knowledge of the regulations. The
acquired knowledge from complying with other govern-
ment regulations lead to compliance with the NHP regu-
lations for large firms, whereas the lack of knowledge of
the NHP regulations leads to noncompliance for some
SMEs.
The finding that those not complying were not avoiding
the regulations, but rather that they were unaware of their
responsibilities to comply, is a phenomenon that has also
been shown by a study of self-reporting about chemical
emissions by American manufacturers. Non-reporters
were generally smaller firms that were ignorant of report-
ing requirements[16].
VIII. Implications of the NHP regulations on the industry
The structure of the NHP industry
As explained in the introduction, very little is known
about the Canadian NHP industry. Nevertheless, three
key characteristics of the industry are known: that 50% of
the NHP industry is comprised of small and medium
sized business, that a few large, multi-million dollar firms
have a significant portion of the market share, and that
Canadian sales for the industry are approximately $4.3
billion. Participants of the study believed that larger com-
panies offer commonly used NHPs, such as vitamins and
minerals, and smaller firms produced more niche prod-
ucts for particular clientele, such as products with several
active ingredients. With these characteristics in mind, the
potential impact of the NHP regulations on the industry
can be assessed.
The NHP regulations and SMEs
Since a significant number of NHP companies are SMEs
and this paper explores the experiences of industry mem-
bers with the new regulations, predictions can be made
about the impact of the regulations on SMEs. A finding of
this study is that three firms were not complying with
them: all three firms were SMEs. These three SMEs were
not deliberately avoiding regulatory compliance. Rather,
employees and/or owners had little to no knowledge of
the regulations.
In addition, employees of smaller firms that were comply-
ing expressed concern about how their firms would sur-
vive in the new regulatory environment. In particular,
participants were frustrated with how the regulations are
being implemented. Furthermore, smaller firms are also
less likely to register products by the appropriate deadline.
Thus, some SMEs are having difficulties in complying
with the product licensing requirements.BMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
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These findings suggest that a possible impact is that some
small firms may not be able to survive the exigencies of
the regulations and close their businesses. Thus, the NHP
industry may become more concentrated as a way to
ensure economies of scale. That is, the current industry
with 50% of SMEs and few large firms with a large market
share may change to an industry with fewer small firms
and large firms having an even greater market share than
the present time. Thus, consolidation of the NHP industry
is likely. If smaller firms are forced to exit the industry,
some may choose to amalgamate with larger firms.
Exit of smaller firms from the industry
If firms that cannot afford to comply with the regulations
are forced to exit the market, consumers may be protected
if marginal firms and products disappeared and that
might lead to greater consumer confidence in the use and
safety of NHPs. These are the potential positive changes
that the NHPD suggested would occur when the regula-
tions were implemented.
On the other hand, it is by no means clear that the small
firms that may exit the industry are currently making infe-
rior products. Participants in this study seemed to think
that smaller firms generally offer specialty products which
certain consumers demand. If these smaller firms are
forced to exit the industry, then many of these specialty
products may no longer be available to consumers. This is
particularly disconcerting, because one role of the NHPD
is to allow for safe, high quality products without restrict-
ing consumer access to NHPs.
The question then becomes, what will consumers do with-
out the products they have enjoyed for years? A potential
outcome is a growth in the unregulated market of NHPs.
So, products that are no longer legally available in Canada
could be sold to consumers through unregulated chan-
nels, thus leaving consumers open to potential harm.
Although illegal, some retail stores or health practitioners
may be willing to provide products that are no longer
available legally in the country. Internet sales of products
imported from other countries for personal use may
increase in response. Overall, the exit of some firms and
loss of products will cause concern for some, but perhaps
few, consumers. This is an area where further research is
needed.
Consolidation of the industry
SME representatives were concerned that the NHP regula-
tions would make it difficult for small firms to survive.
Participants suggested that industry consolidation could
lead to less innovative products and practices in Canada
because many believe that the SMEs are the main innova-
tors in the industry. Participants suggested that less inno-
vation might occur because NHPs often cannot be
patented and thus historically firms have generally not
invested significantly in research and development. Com-
pliance costs may also decrease the likelihood of financial
investment into innovation. In contrast, other compo-
nents of the regulations (such as the Natural Health Prod-
ucts Research Program) and the ability to make label
claims based on scientific research may actually encourage
research and innovation. Whether regulations encourage
or discourage innovation is a current policy debate[17]. It
remains unclear how the NHP Regulations may affect
innovation in Canada.
SME employees also suggested that the regulations might
encourage large foreign companies to sell more of their
products in Canada. If some companies exit the industry,
there may be a demand for products that might be filled
by American, Asian, and European companies, which
have already captured 75% of the global nutritional prod-
uct industry [18]. As suggested by this research, larger
companies are more capable of processing a PLA and thus
able to sell products with the new NPN. Canadian NHP
producers may not welcome the growth of foreign invest-
ments in the industry, but consumers may enjoy the diver-
sity of product lines.
Large firms representatives also predicted consolidation of
the industry and viewed this potential change as a positive
feature of the NHP regulations because fewer firms oper-
ating in the industry would offer greater market opportu-
nities. In addition, large firms that are presently operating
in the industry have the advantage of familiarizing them-
selves with the NHP Regulations during the early stages of
implementation. Thus, the NHP Regulations appear to
serve the incumbents. This means that Canadian entrepre-
neurs may encounter greater barriers for entry into the
market, particularly for small business owners; however,
those already in the industry would appear to have an
advantage.
Study limitations
The main limitation of this study is that the companies
were selected based on their sale of chondroitin and/or
glucosamine. These companies may be different from the
other companies in the industry due to the nature of prod-
ucts they sell. Also, a large number of companies declined
to participate. However, a maximum variation sample
and saturation were successfully attained in the study, and
data collection was purposely stopped after 20 interviews
were completed because it appeared that additional inter-
views would not have provided significant new informa-
tion. Despite this, it is not possible to determine whether
those companies that declined to participate are comply-
ing with the new regulations. Another limitation of the
study is that the response to compliance deadlines was
based on self-reporting. However, participants were gen-BMC Health Services Research 2006, 6:63 http://www.biomedcentral.com/1472-6963/6/63
Page 10 of 11
(page number not for citation purposes)
erally candid during interviews, leaving no reason to
believe the information was misrepresented. Finally,
some interviews were conducted in person, while others
were completed using the telephone creating the potential
that different quality or types of data may be collected
depending on the method used. However, analysis of the
interviews did not reveal any differences.
Conclusion
In conclusion, the majority of NHP companies in the
study are complying with the NHP regulations to varying
degrees. Participants agree with the goal of the NHPD and
the need for regulations. Compliance with the Regula-
tions is associated with firm size as well as knowledge of
the Regulations. That is, large firms that are familiar with
the set of laws are more likely to comply with the Regula-
tions. These findings suggest that smaller firms may exit
the industry, leading to industry consolidation in Canada.
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